awmsg logo



tenofovir disoproxil fumarate (Viread®)


Reference No. 303

Publication date:
06/10/2008


Appraisal information

tenofovir disoproxil fumarate (Viread®) 245 mg film-coated tablet


Company: Gilead Sciences Ltd
BNF category: Infections
NMG meeting date: 16/07/2008
AWMSG meeting date: 13/08/2008
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 1208
Ministerial ratification: 29/09/2008

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA173) NICE GUIDANCE ISSUED JULY 2009 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Tenofovir (Viread®) is recommended for use within NHS Wales for the treatment of chronic hepatitis B in adults with compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis. AWMSG is of the opinion that tenofovir (Viread®) should be initiated only by healthcare professionals experienced in the management of viral hepatitis; however continued care may be suitable for provision under shared care arrangements. Note (posted 8/12/08): The conclusion reached by the Interface Pharmacist Group and endorsed by AWMSG was that tenofovir (Viread®) is not suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download